These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 15144904

  • 1. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH, Wu SC, Chen WS, Yen CC, Yang MH, Tsai YC, Chen PM.
    Biochem Biophys Res Commun; 2004 Jun 04; 318(3):764-72. PubMed ID: 15144904
    [Abstract] [Full Text] [Related]

  • 2. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R, Zentilin L, Fanin R, Giacca M.
    Cancer Gene Ther; 2002 Jan 04; 9(1):71-86. PubMed ID: 11916246
    [Abstract] [Full Text] [Related]

  • 3. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y, Chen YZ, Huang HF, Chen P, Lu LH.
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep 04; 35(9):859-63. PubMed ID: 12958661
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ribozyme-mediated cleavage of the bcr/abl transcript expressed in chronic myeloid leukemia.
    Wright L, Wilson SB, Milliken S, Biggs J, Kearney P.
    Exp Hematol; 1993 Dec 04; 21(13):1714-8. PubMed ID: 8243570
    [Abstract] [Full Text] [Related]

  • 6. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity.
    Shore SK, Nabissa PM, Reddy EP.
    Oncogene; 1993 Nov 04; 8(11):3183-8. PubMed ID: 8414522
    [Abstract] [Full Text] [Related]

  • 7. Cleavage of BCR/ABL mRNA by synthetic ribozymes--effects on the proliferation rate of K562 cells.
    Lange W.
    Klin Padiatr; 1995 Nov 04; 207(4):222-4. PubMed ID: 7564157
    [Abstract] [Full Text] [Related]

  • 8. Investigating and improving the specificity of ribozymes directed against the bcr-abl translocation.
    James H, Mills K, Gibson I.
    Leukemia; 1996 Jun 04; 10(6):1054-64. PubMed ID: 8667643
    [Abstract] [Full Text] [Related]

  • 9. [Study on the in vitro cleavage abilities of ribozymes specific to different sites of bcr-abl fusion gene and their induction of apoptosis in K562 cells].
    Feng Q, Sun B, Zhao Y.
    Zhonghua Yi Xue Za Zhi; 2000 Feb 04; 80(2):127-30. PubMed ID: 11798747
    [Abstract] [Full Text] [Related]

  • 10. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 11. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A, Banerjee D, Chandra S, Banerjee S.
    J Gene Med; 2006 Oct 01; 8(10):1251-61. PubMed ID: 16952195
    [Abstract] [Full Text] [Related]

  • 12. Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
    Vaerman JL, Lewalle P, Martiat P.
    Stem Cells; 1993 Oct 01; 11 Suppl 3():89-95. PubMed ID: 8298481
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Effects of anti-ABL tyrosine kinase intrabody on the growth of K562 cells in nude mice].
    Xu D, Song JM, Hu Y, Guo H, Cao DJ, Wang P, Liu H, Zhao CH.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Feb 01; 24(1):11-4. PubMed ID: 12905832
    [Abstract] [Full Text] [Related]

  • 15. Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
    Warashina M, Kuwabara T, Taira K.
    Nucleic Acids Symp Ser; 1997 Feb 01; (37):213-4. PubMed ID: 9586075
    [Abstract] [Full Text] [Related]

  • 16. Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence.
    Sugimoto T, Ijima K, Hisatomi H, Murayama T, Mizuno I, Hato A, Imoto S, Nishimura R, Koizumi T.
    Am J Hematol; 2004 Oct 01; 77(2):164-6. PubMed ID: 15389825
    [Abstract] [Full Text] [Related]

  • 17. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S, Chai YB, Liu F, Zhang XY, Jia W, Xie X, Yu WQ, Shang ZC, Jin BQ, Sun BZ.
    Zhonghua Yi Xue Za Zhi; 2005 Jan 19; 85(3):198-202. PubMed ID: 15854468
    [Abstract] [Full Text] [Related]

  • 18. Improved specificity of ribozyme-mediated cleavage of bcr-abl mRNA.
    Kearney P, Wright LA, Milliken S, Biggs JC.
    Exp Hematol; 1995 Aug 19; 23(9):986-9. PubMed ID: 7543419
    [Abstract] [Full Text] [Related]

  • 19. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R, Gandhi V, Plunkett W.
    Cancer Res; 2006 Nov 15; 66(22):10959-66. PubMed ID: 17108134
    [Abstract] [Full Text] [Related]

  • 20. Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
    Wright LA, Milliken S, Biggs JC, Kearney P.
    Antisense Nucleic Acid Drug Dev; 1998 Feb 15; 8(1):15-23. PubMed ID: 9512092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.